FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.

References

• Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma–diagnosis and treatment. Lancet Oncol 2004; 5: 19–26
   PubMed Web of Science ®Google Scholar
• Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302–10
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123–30
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20–5
   PubMed Web of Science ®Google Scholar
• Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 46: 983–95
   PubMed Web of Science ®Google Scholar
• Jaffe ES HNL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004; 15: 1699–704
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018–27
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen MT, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. Blood 2006; 107: 52–9
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–4
   PubMed Web of Science ®Google Scholar
• de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29–37
   PubMed Web of Science ®Google Scholar
• Guay C., Lépine M, Verreault J, Bénard F. Prognostic value of PET using 18F-FDG in Hodgkin′s disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225–31
   PubMed Web of Science ®Google Scholar
• Facey K, Bradbury I, Laking A, Payne E. “Ultra rapid review. Positron Emission Tomography (PET) Imaging in Cancer Management” HTA July 2004.
   Google Scholar
• Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004; 52: 19–32
   Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429–33
   PubMed Web of Science ®Google Scholar
• Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol, vol 15, No 3 (March), 1997:1123–1130.
   Google Scholar
• Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 1997; 314: 343–6
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?. Eur J Nucl Med 2000; 27: 1564–78
   PubMedGoogle Scholar
• Dobert N, Menzel C, Hamscho N, Wordehoff W, Kranert WT, Grunwald F. Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin's and non-Hodgkin's lymphoma. Q J Nucl Med Mol Imaging 2004; Vol 48, No 1:33–38.
   Google Scholar
• de Hemricourt E, De Boeck K, Hilte F, Abib A, Kockx M, Vandevivere J, et al. Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Mol Imaging Biol 2003; 5: 15–9
   PubMedGoogle Scholar
• Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999; 26: 31–8
   Google Scholar
• Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11(Suppl 1)147–50
   PubMed Web of Science ®Google Scholar
• Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001; 8: 1393–9
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793–800
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181–4
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 2001; 115: 272–8
   PubMed Web of Science ®Google Scholar